Topical decongestants: myth and reality
https://doi.org/10.21518/2079-701X-2018-12-40-43
Abstract
Nasal breathing plays an important role in the respiratory function, which ensures that a person consumes appropriate levels of air. Nasal obstruction causes a person to consume air mainly through the mouth, which impairs the numerous functions of the nose. This leads first to functional abnormalities, and then to morphological and structural changes. Topical decongestants that have the strongest and fastest effect are the most popular drugs to manage rapidly nasal obstruction. The main nasal decongestants can be divided into two groups: sympathomimetic amines: primary aliphatic, phenolic and non-phenolic compounds, as well as imidazoline derivatives. Among modern vasoconstrictive drugs, Otrivin® complex showed good results. The drug contains xylometazoline and ipratropium bromide. Application of this drug strictly according to the instructions and for no more than 15 days guarantees the absence of severe local and systemic complications.
About the Authors
N. A. Miroshnichenko
A.I.Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
A. Yu. Ovchinnikov
A.I.Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
References
1. Passali D, Buccellam G, Vetuschi A, Bellussi L. Nasal vascularization: experiences using the microcorrosion technique in human foetuses. Rhinology, 1992, 30(2): 81-88. The paper is the first and, to the authors’ knowledge unique article describing in details the complex nasal vascularisation.
2. Kennedy DW, Passali D, Lund V. International conference on sinus disease terminology staging therapy Ann. Otol. Rhinol. Laryngol., 1995, 104(Suppl.): 167-183.
3. Togias A. Mechanism of nose-lung interaction. Allergy, 1999, 54(Suppl.57): 94-100.
4. Taveener D. Nasal decongestants for the common cold Cochrane Database Syst. Rev. (2000) 2: CD001953.
5. Passali D: Terapia sintomatica. In: Rinopatia Vasomotoria Spedfica. Pacini (Ed), Pisa, Italy (1999): 169-207.
6. Bellussi L, Becchini G, Marzetti A Passali D: Comparative study of the effect of vasoconstrictive and balsamic agents in the decongestant nasal test. Acta Otolarynol. Ital., 1998, 18(6): 379-386.
7. Caenen M, Hamels K, Deron P, Clement P: Comparison of decongestive capacity of xylometazoline and pseudoefedrine with rhinomanometry and MRI. Rhinology (2005) 43(3): 205-209. In this article the efficacy of decongestant drugs is demonstrated by means of objective and standardised tests, such as MRI and rhinomanometry.
8. Graf P Enerdal J, Hallen H. Ten days’ use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis. Arch. Otolaryngol. HNS, 1999, 125: 1128-1132.
9. Graf P, Juto JE. Decongestion effect and rebound swelling of the nasal mucosa during 4 week use of oxymetazoline. ORL J. Otorhinolaryngol. Relat. Spec., 1994, 56: 131-134.
10. Patient Information Leaflet for Otivin® complex.
Review
For citations:
Miroshnichenko NA, Ovchinnikov AY. Topical decongestants: myth and reality. Meditsinskiy sovet = Medical Council. 2018;(12):40-43. (In Russ.) https://doi.org/10.21518/2079-701X-2018-12-40-43
Views:
718
Email this article 